has won FDA approval for its abbreviated new drug applications (ANDAs) for generic versions of Urecholine tablets (bethanechol chloride tablets USP), 5 mg, 10 rag, 25 mg and 50 mg.
markets Urecholine for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
Prescription drugs like Urecholine
(bethanechol) and Reglan (metoclopramide) strengthen the esophageal sphincter and make the stomach empty faster.
A few other medications, such as Carafate, Urecholine
and Prilosec are also available.
The aim of this study was to evaluate the usefulness of transvaginal electrical stimulation at 200 Hertz in women with symptomatic, nonobstructive urinary retention and compare the results to transvaginal electrical stimulation at 200 Hertz with concomitant Urecholine
The evolution of the new entity came about through the purchase of the trademark and active ingredient for Urecholine
(bethanechol chloride tablets, USP) from the innovator company.
for the treatment of acute post-operative and post partum non-obstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.
is the initial product launch of Odyssey, which has additional brand name product introductions in the planning stages.
Its products currently consist of Urecholine
(bethanechol chloride) the unique pharmaceutical option for treatment of non-obstructive urinary retention; Vivactil (protriptylline HCl) and Surmontil (trimipramine maleate) for the treatment of symptoms of mental depression; Antabuse (disulfiram) used in treatment of alcohol abuse as an aid to supportive and psychotherapeutic treatment; Nystatin Vaginal tablets for the treatment of vaginal candidiasis and Custodiol HTK solution, a new product in the US market used for the perfusion and preservation of donor organs.